The most recent study has been published in 2023, demonstrating the safety and effectiveness of the CamAPS FX HCL system compared with standard insulin therapy in an open-label randomized crossover study including 26 adults with type 2 diabetes: TIR was 66.3% with closed-loop therapy versus 32.3% with control therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.